<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958425</url>
  </required_header>
  <id_info>
    <org_study_id>CDHA-RS/2009-252</org_study_id>
    <nct_id>NCT00958425</nct_id>
  </id_info>
  <brief_title>Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty</brief_title>
  <official_title>Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty: a Phase III Double-blinded, Single-centred, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of hyaluronic acid gel injections
      compared to saline injections in improving scar quality in patients undergoing breast
      reduction surgery. Hyaluronic acid has been implicated in scarless fetal healing, and the
      investigators therefore hypothesize that injections of hyaluronic acid gel into breast
      reduction incisions will improve their appearance compared to injections of saline.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Failure of funding
  </why_stopped>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rasch analysis-modified Objective Scar Assessment Score (OSAS) value</measure>
    <time_frame>12 months post-operatively</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cicatrix</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid gel</intervention_name>
    <description>Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once</description>
    <arm_group_label>Hyaluronic acid gel</arm_group_label>
    <other_name>Prevelle</other_name>
    <other_name>Restylane</other_name>
    <other_name>Hyalorunan</other_name>
    <other_name>Hyaluronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Normal saline, 0.9 mL, intradermal over 2 cm area, once</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adequate organ function (BUN &lt; 4.0 mmol/L; serum creatinine &lt; 120 micromol/L; Hgb &gt;
             100 g/L; WBC &gt; 4,000/mm3 and &lt; 12,000/mm3; platelets &gt; 100,000/mm3)

          -  age 18 years or older, with a minimum life expectancy of 2 years

          -  current non-smoker

          -  American Society of Anaesthesiology score of 1 or 2

          -  ability to provide informed consent

        Exclusion Criteria:

          -  previous history of breast surgery; known allergy to polyglactin, poliglecaprone, or
             injectable hyaluronic acid gel (Restylane or Prevelle)

          -  history of current or recent (&lt;2 months) immunosuppression

          -  documented hypersensitivity to streptococcal products

          -  acute or chronic skin diseases such as folliculitis or psoriasis

          -  history of bleeding dyscrasia or active anticoagulation (INR&gt;2.0)

          -  pregnancy or active breast-feeding

          -  any additional surgical procedures performed in the same surgical session in the same
             anatomical region

          -  personal or family history of susceptibility to keloid or hypertrophic scar formation

          -  Fitzpatrick skin type 5 or 6.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Bezuhly, MD MSc SM FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capital District Health Authority; Dalhousie University</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Michael Bezuhly</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

